Leuthold Group LLC Sells 315 Shares of Cencora, Inc. (NYSE:COR)

Leuthold Group LLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 0.9% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,087 shares of the company’s stock after selling 315 shares during the quarter. Leuthold Group LLC’s holdings in Cencora were worth $7,905,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Kingswood Wealth Advisors LLC acquired a new stake in Cencora in the 2nd quarter worth about $655,000. TD Asset Management Inc acquired a new stake in Cencora during the first quarter worth approximately $95,313,000. LSV Asset Management bought a new position in Cencora during the 1st quarter worth $3,579,000. Cairn Investment Group Inc. acquired a new position in Cencora in the 1st quarter valued at $2,294,000. Finally, Lake Street Advisors Group LLC bought a new stake in shares of Cencora during the 1st quarter valued at $836,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Robert W. Baird lowered their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. JPMorgan Chase & Co. raised their target price on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Finally, Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock valued at $1,070,392,799 over the last 90 days. Company insiders own 15.80% of the company’s stock.

Cencora Stock Down 2.6 %

NYSE:COR opened at $228.48 on Thursday. Cencora, Inc. has a one year low of $178.21 and a one year high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company has a market cap of $45.57 billion, a PE ratio of 25.00, a P/E/G ratio of 1.55 and a beta of 0.44. The firm’s 50 day simple moving average is $234.64 and its 200 day simple moving average is $233.23.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the prior year, the business posted $2.92 earnings per share. Cencora’s quarterly revenue was up 10.8% on a year-over-year basis. On average, research analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.89%. Cencora’s payout ratio is 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.